Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyHealthfirst Nucleic Acid Probe Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedHealthfirstPolicy PO-RE-033v6

    Identification of Microorganisms using Nucleic Acid Probes Reimbursement Policy

    Customize your policy alerts

    Sign up for Healthfirst Policy PO-RE-033v6 alerts

    Get alerted when Policy PO-RE-033v6 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This reimbursement policy governs coverage of individual direct-probe, amplified-probe, and quantification nucleic acid tests used to identify microorganisms. Coverage is subject to the member's benefit coverage and code-specific criteria; simultaneous amplified-probe and quantification testing for the same organism in one encounter does not meet coverage criteria.

    Policy Summary
    PayerHealthfirst
    PolicyIdentification of Microorganisms using Nucleic Acid Probes Reimbursement Policy
    Policy CodePolicy PO-RE-033v6
    Change TypeModified
    Effective DateNovember 1, 2026
    Last ReviewJun 3, 2026
    Next Review DateNot specified
    Key ActionDo not simultaneously order an amplified probe and quantification test for the same organism during a single encounter.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The policy added Pneumocystis jirovecii amplified probe CPT 87594 and Rubeola virus amplified probe CPT 87638 as MCC in coverage criterion CC1.

    Non-vaginal Candida species and associated codes were removed from the coverage table because the same codes apply to all Candida species.

    Direct probes for Chlamydia pneumoniae, Cytomegalovirus, Legionella pneumophila, and Mycoplasma pneumoniae changed from MCC to DNMCC.

    The policy revised CC1 and CC2 to exclude simultaneous ordering of an amplified probe and quantification for the same organism during one encounter.

    Mycoplasma genitalium was removed from this policy's coverage table because its testing management is addressed in G2157.

    The HHV-6 direct probe CPT 87531 changed from MCC to DNMCC.

    CPT codes 87480, 87481, 87482, and 87563 were removed from the policy.

    2New amplified-probe codes added as covered
    4Direct-probe organism groups changed to not covered
    1Same-organism modality restriction
    20Organisms or categories in the coverage table
    3Nucleic acid test modalities addressed
    MCC / DNMCCCoverage status abbreviations

    Coverage Criteria

    Individual Probe Coverage and Ordering Restriction

    Coverage status for nucleic acid identification is specified by microorganism and testing modality. MCC means the test meets coverage criteria; DNMCC means the test does not meet coverage criteria.

    Coverage status by microorganism and modality

    • Bartonella henselae or quintana: amplified probe CPT 87471 — MCC; quantification CPT 87472 — DNMCC.
    • Chlamydia pneumoniae: direct probe CPT 87485 — DNMCC; amplified probe CPT 87486 — MCC; quantification CPT 87487 — DNMCC.
    • Clostridium difficile: amplified probe CPT 87493 — MCC.
    • Cytomegalovirus: direct probe CPT 87495 — DNMCC; amplified probe CPT 87496 — MCC; quantification CPT 87497 — MCC.
    • Enterococcus, vancomycin-resistant (e.g., enterococcus vanA, vanB): amplified probe CPT 87500 — MCC.
    • Enterovirus: amplified probe CPT 87498 — MCC.
    • Hepatitis G: direct probe CPT 87525 — DNMCC; amplified probe CPT 87526 — DNMCC; quantification CPT 87527 — DNMCC.
    • Herpes virus-6: direct probe CPT 87531 — DNMCC; amplified probe CPT 87532 — DNMCC; quantification CPT 87533 — MCC.
    • Legionella pneumophila: direct probe CPT 87540 — DNMCC; amplified probe CPT 87541 — MCC; quantification CPT 87542 — DNMCC.
    • Orthopoxvirus: amplified probe CPT 87593 — MCC.
    • Pneumocystis jirovecii: amplified probe CPT 87594 — MCC.
    • Mycoplasma pneumoniae: direct probe CPT 87580 — DNMCC; amplified probe CPT 87581 — MCC; quantification CPT 87582 — DNMCC.
    • Respiratory syncytial virus: amplified probe CPT 87634 — MCC.
    • Rubeola virus: amplified probe CPT 87638 — MCC.
    • Staphylococcus aureus: amplified probe CPT 87640 and CPT 87641 — MCC.

    Mpox PCR Testing

    Mpox testing is recommended when clinical findings or epidemiologic circumstances create a reasonable suspicion of infection.

    Recommended clinical circumstances

    • Test patients with probable mpox using an Mpox virus-specific PCR or an orthopoxvirus-specific PCR assay, with confirmation through sequencing.
    • Consider testing when a patient develops a rash with fever or a feeling of discomfort or illness.
    • For suspected mpox, collect a viral swab in viral culture or viral transport medium from an open sore, vesicle, ulcer, or crusted vesicle; obtain a throat swab when pharyngeal lesions are present.
    • For high-risk contacts of a confirmed or highly probable case who develop systemic symptoms without a rash or lesions that can be sampled, a viral throat swab may be obtained. A negative throat swab does not eliminate the need for monitoring, isolation, reassessment, or repeat sampling if additional symptoms develop.

    Post-Recovery Mpox Testing

    Following recovery from mpox infection, perform MPXV PCR on semen samples from 12 weeks through 6 months when any of the following circumstances applies.

    Post-recovery testing indications

    • The patient is undergoing fertility treatment or planning pregnancy.
    • The patient is undergoing planned semen storage, such as before chemotherapy.
    • The patient has an immunocompromised sexual partner, including a pregnant partner.
    • The patient is concerned about transmission to one or more sexual partners for any other reason and requests testing from the clinician.
    • Where necessary, obtain oropharyngeal and/or rectal swabs in addition to semen testing.

    Pneumocystis jirovecii Specimen Acceptance

    Pneumocystis jirovecii testing is accepted only when all applicable specimen and clinical requirements are met.

    Specimen acceptance requirements

    • The patient is immunocompromised, has risk factors, and has clinical symptoms suggestive of Pneumocystis jirovecii pneumonia; this information must be documented on the requisition.

      Absence of the required clinical information on the requisition leads to specimen rejection.

    • No more than one specimen per patient per week is submitted for testing.

      Pooled specimens are accepted.

    • The specimen is not collected using a swab.

      Swab specimens are not acceptable.

    • The specimen is not expectorated sputum.

      Expectorated sputum specimens are not acceptable.

    PCP Diagnostic Testing

    Definitive PCP diagnosis requires organism detection in an appropriate clinical specimen.

    Acceptable diagnostic approaches

    • Demonstration of Pneumocystis jirovecii by histopathology or cytopathology in tissue, bronchoalveolar lavage (BAL) fluid, or induced sputum.
    • Detection of Pneumocystis by immunofluorescence, histochemistry, or PCR in induced sputum or BAL fluid.

    CC1 Additions

    The 2026 literature review added two amplified-probe tests to CC1 as tests that meet coverage criteria.

    CC1 additions

    • Pneumocystis jirovecii amplified probe, CPT 87594 — MCC.
    • Rubeola virus amplified probe, CPT 87638 — MCC.

    CPT codes 87594 and 87638 were added to the policy as MCC amplified-probe tests: 87594 for Pneumocystis jirovecii and 87638 for Rubeola virus.

    Simultaneous ordering of an amplified probe and quantification for the same organism in a single encounter does not meet coverage criteria.

    Direct-probe testing for the organisms listed in the policy does not meet coverage criteria.

    COVERAGE CRITERIA: Simultaneous ordering of amplified probe and quantification for the same organism in a single encounter does not meet coverage criteria.

    COVERAGE CRITERIA: Pneumocystis jirovecii specimens collected using a swab and expectorated sputum specimens are unacceptable for testing.

    COVERAGE CRITERIA: Detection of Pneumocystis jirovecii by PCR in respiratory samples from a patient without symptoms or signs of respiratory disease should not, by itself, trigger initiation of PCP treatment.

    COVERAGE CRITERIA: Direct-probe tests do not meet coverage criteria.

    COVERAGE CRITERIA: Amplified-probe and quantification testing for the same organism may not be ordered simultaneously in a single encounter.

    COVERAGE CRITERIA: In the policy table, MCC means the test meets coverage criteria and DNMCC means the test does not meet coverage criteria.

    Applicable Codes and Coding Thresholds

    Codes marked MCC — meets coverage criteriaCPTCovered
    87471Bartonella henselae or quintana — amplified probe
    87486Chlamydia pneumoniae — amplified probe
    87493Clostridium difficile — amplified probe
    87496Cytomegalovirus — amplified probe
    87497Cytomegalovirus — quantification
    87500Enterococcus, vancomycin-resistant (e.g., enterococcus vanA, vanB) — amplified probe
    87498Enterovirus — amplified probe
    87532Herpes virus-6 — amplified probe
    87541Legionella pneumophila — amplified probe
    87593Orthopoxvirus — amplified probe
    1–10 of 17
    1/2
    Codes marked DNMCC — does not meet coverage criteriaCPTNot Covered
    87472Bartonella henselae or quintana — quantification
    87485Chlamydia pneumoniae — direct probe
    87487Chlamydia pneumoniae — quantification
    87495Cytomegalovirus — direct probe
    87525Hepatitis G — direct probe
    87526Hepatitis G — amplified probe
    87527Hepatitis G — quantification
    87531Herpes virus-6 — direct probe
    87540Legionella pneumophila — direct probe
    87542Legionella pneumophila — quantification
    1–10 of 12
    1/2
    Applicable CPT CodesCPT
    87471Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, amplified probe technique.
    87472Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, quantification.
    87485Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, direct probe technique.
    87486Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique.
    87487Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, quantification.
    87493Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique.
    87580Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, direct probe technique.
    87581Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, amplified probe technique.
    87582Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, quantification.
    87593Infectious agent detection by nucleic acid (DNA or RNA); Orthopoxvirus, such as monkeypox virus, cowpox virus, or vaccinia virus, amplified probe technique, each.
    1–10 of 13
    1/2
    Applicable CPT Codes with source-code formatting lossCPT
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, direct probe technique.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, amplified probe technique.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, quantification.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); enterovirus, amplified probe technique, includes reverse transcription when performed.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); hepatitis G, direct probe technique.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); hepatitis G, amplified probe technique.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); hepatitis G, quantification.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, direct probe technique.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, amplified probe technique.
    not legible in source extractInfectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, direct probe technique.
    1–10 of 14
    1/2
    Added as MCCCPTCovered
    87594Pneumocystis jirovecii amplified probe
    87638Rubeola virus amplified probe
    Revised or removed CPT codesCPT
    87531HHV-6 direct probe — changed from MCC to DNMCC
    87480CPT code removed from the policy
    87481CPT code removed from the policy
    87482CPT code removed from the policy
    87563CPT code removed from the policy
    HHV-6 quantitative PCR
    Active infection threshold>200 copies per mL or 20 copies per microgram of DNA
    Pneumocystis jirovecii testing
    Testing frequencyOnly one specimen per patient per week will be tested

    Provider Requirements and Billing Impacts

    Documentation Required

    PJP Risk Factors and Symptoms Must Be Documented

    For suspected Pneumocystis jirovecii pneumonia (PJP), document on the requisition that the patient is immunocompromised and has risk factors and clinical symptoms suggestive of PJP infection.

    Note

    LDT Validation and CLIA Context

    Laboratory-developed tests (LDTs) must be validated and performed in-house under applicable CLIA requirements. LDTs are regulated by CMS as high-complexity tests under CLIA '88 and are not FDA-approved or cleared, although FDA clearance or approval is not currently required for clinical use.

    Denial Risk

    Clinical and Technical Background

    Nucleic acid hybridization methods use complementary DNA properties to anneal fragments from different sources and identify microorganisms. The policy discusses PCR, ligase- or helicase-dependent amplification, transcription-mediated amplification, and related technologies that can detect pathogens in blood cultures and other clinical specimens with high sensitivity and specificity. Operational limitations may include contamination, lack of assay standardization or validation, complex interpretation, and increased cost. The policy addresses individual probes rather than multiplex panels.

    Terms and Abbreviations

    Definitions
    MCCTest meets the policy's coverage criteria.
    Definitions
    DNMCCTest does not meet the policy's coverage criteria.
    Definitions
    Nucleic acid hybridizationUses complementary DNA properties to anneal DNA fragments from different sources; these techniques are used in PCR and FRET methods to identify microorganisms.
    Abbreviations
    ASM

    Covered Clinical Indications

    Covered Microorganism Identification

    Coverage is available for identification of microorganisms listed in the policy when the individual modality and code are marked MCC.

    Covered microorganism testing

    • Amplified probe or quantification: The test identifies a microorganism listed in the policy using an individual amplified-probe or quantification code marked MCC.
    • Other listed MCC modality/code: The test uses another listed microorganism, modality, and procedure-code combination marked MCC in the policy table.

    RSV Diagnosis

    Highly sensitive NAATs, including PCR, may be used for RSV diagnosis.

    RSV diagnostic testing:

    Testing Frequency and Timing

    Pneumocystis jirovecii testing
    Specimen limitOnly one specimen per patient per week will be tested.
    MPXV PCR testing
    Post-recovery timingFrom 12 weeks through 6 months after recovery from infection.

    Ordering Requirements

    Note

    Follow ordering and PJP requisition requirements

    Do not simultaneously order amplified-probe and quantification tests for the same organism in one encounter, because simultaneous ordering does not meet coverage criteria. For PJP testing, state on the requisition that the patient is immunocompromised and include relevant risk factors and clinical symptoms suggestive of PJP infection.

    • Swab-collected and expectorated sputum specimens are not acceptable for PJP testing.
    • Only one PJP specimen per patient per week will be tested.

    Services Not Meeting Coverage Criteria

    The policy does not cover individual organism, modality, and code combinations marked DNMCC in the coverage table. It also excludes simultaneous amplified-probe and quantification testing for the same organism in a single encounter. Direct-probe testing identified in the policy—including direct probes for Chlamydia pneumoniae, Cytomegalovirus, Legionella pneumophila, Mycoplasma pneumoniae, and HHV-6—does not meet coverage criteria.

    Policy Summary
    PayerHealthfirst
    PolicyIdentification of Microorganisms using Nucleic Acid Probes Reimbursement Policy
    Policy CodePolicy PO-RE-033v6
    Change TypeModified
    Effective DateNovember 1, 2026
    Last ReviewJun 3, 2026
    Next Review DateNot specified
    Key ActionDo not simultaneously order an amplified probe and quantification test for the same organism during a single encounter.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Codes and Coding ThresholdsProvider Requirements and Billing ImpactsClinical and Technical BackgroundTerms and AbbreviationsCovered Clinical IndicationsTesting Frequency and TimingOrdering RequirementsServices Not Meeting Coverage Criteria
    If follow-up testing is required because of clinical deterioration or to inform discharge from isolation to an inpatient setting, obtain a lesion swab and throat swab in viral transport medium, an EDTA blood sample, and a urine sample in a universal sterile container.
  1. All diagnostic samples from individuals testing positive for mpox should undergo clade confirmation; send positive samples for clade-specific testing when local testing services cannot differentiate clades.
  2. Code-Specific DNMCC Status

    A requested test marked DNMCC (does not meet coverage criteria) does not meet Healthfirst coverage criteria and may be denied.

    • Examples identified in the policy include CPT 87472, 87485, 87487, and 87495.
    • Coverage status is determined by the procedure code and testing modality listed in the policy table.
    Billing Rule

    Avoid Duplicate Modality Ordering

    Do not order amplified-probe and quantification testing for the same organism in a single encounter. Simultaneous ordering does not meet coverage criteria.

    Documentation Required

    PJP Requisition and Specimen Rejection Criteria

    PJP testing requests are accepted only when the requisition documents an immunocompromised patient with risk factors and clinical symptoms suggestive of PJP infection. Missing clinical information or an unacceptable specimen may result in rejection.

    • Only one specimen per patient per week will be tested; pooled specimens are accepted.
    • Swab-collected specimens are not acceptable.
    • Expectorated sputum specimens are not acceptable.
    Denial Risk

    Same-Encounter Testing Exclusion

    Avoid simultaneous amplified-probe and quantification testing for the same organism during one encounter, because the combination does not meet coverage criteria.

    Denial Risk

    Direct Probes Designated DNMCC

    Direct-probe tests designated DNMCC do not meet coverage criteria. The policy revision specifically changed HHV-6 direct-probe CPT 87531 to DNMCC; direct probes in the policy do not meet coverage criteria.

    • CPT 87531 — HHV-6 direct probe: DNMCC.
    Billing Rule

    Coding and Billing Noncompliance

    Providers must follow applicable coding, billing, reimbursement, modifier, duplicate-claim, and coverage guidelines. Failure to comply may result in denial or recoupment of claim payment.

    • Healthfirst edits incorporate CMS and NCCI standards, CPT, HCPCS, ICD-10, revenue-coding, and applicable New York State requirements.
    • Reimbursement remains subject to the member's evidence of coverage, applicable state and federal requirements, and the provider participation agreement.
    American Society of Microbiology
    Abbreviations
    CDCCenters for Disease Control and Prevention
    Abbreviations
    CDIClostridioides difficile infection
    Abbreviations
    CIDTCulture-independent diagnostic test
    Abbreviations
    CMVCytomegalovirus
    Abbreviations
    CPTCurrent procedural terminology
    Abbreviations
    DFADirect fluorescent antibody testing
    Abbreviations
    DNADeoxyribonucleic acid
    Abbreviations
    EVDEbola virus disease
    Abbreviations
    FDAFood and Drug Administration
    Abbreviations
    FRETFluorescent resonance energy transfer
    Abbreviations
    HHV-6Human herpesvirus 6
    Abbreviations
    HIVHuman immunodeficiency virus
    Abbreviations
    HIVMAHuman Immunodeficiency Virus Medicine Association
    Abbreviations
    IDSAInfectious Diseases Society of America
    Abbreviations
    ITSInternal transcribed region
    Terms
    MpoxMonkeypox
    Abbreviations
    MRSAMethicillin-Resistant Staphylococcus Aureus
    Abbreviations
    NAATNucleic acid amplification test
    Abbreviations
    NGUNongonococcal urethritis
    Abbreviations
    NIHNational Institutes of Health
    Abbreviations
    PCRPolymerase chain reaction
    Abbreviations
    PIDPelvic inflammatory disease
    Abbreviations
    qPCRQuantitative polymerase chain reaction
    Abbreviations
    rDNARecombinant deoxyribonucleic acid
    Abbreviations
    RNARibonucleic acid
    Abbreviations
    rRT-PCRReal-time reverse transcriptase-polymerase chain reaction
    Abbreviations
    RSVRespiratory syncytial virus infection
    Abbreviations
    RT-PCRReverse transcriptase-polymerase chain reaction
    Abbreviations
    SARSSevere acute respiratory syndrome
    Revision definitions
    MCCMeets coverage criteria.
    Revision definitions
    DNMCCDoes not meet coverage criteria.
    Use a highly sensitive nucleic acid amplification test, including PCR, to diagnose RSV in a patient with suspected RSV infection.

    Probable or Suspected Mpox

    PCR testing is appropriate when mpox is probable or suspected in the circumstances described below.

    Probable or suspected mpox

    • The patient has a probable case and is tested with mpox-virus-specific PCR or orthopoxvirus-specific PCR, followed by sequencing confirmation as recommended by the ECDC.
    • A viral swab is obtained from one or more vesicles, ulcers, or crusted vesicles.
    • A throat swab is obtained for pharyngeal lesions or for a high-risk contact with systemic symptoms but no rash or sampleable lesions.

    Suspected Pneumocystis jirovecii Pneumonia or PCP

    Testing is directed to immunocompromised patients with risk factors and compatible symptoms, using appropriate respiratory specimens.

    Suspected PJP/PCP

    • The patient is immunocompromised and has risk factors and clinical symptoms suggestive of PJP infection.
    • Appropriate specimen and detection method

      • Pneumocystis is demonstrated histopathologically or cytopathologically in tissue, bronchoalveolar lavage fluid, or induced sputum.
      • Pneumocystis is detected by immunofluorescence, histochemistry, or PCR in induced sputum or bronchoalveolar lavage fluid.

    Suspected Active or Localized HHV-6 Infection

    Quantitative testing of blood and tissue is preferred when evaluating suspected active or localized HHV-6 infection.

    Active or localized HHV-6 infection

    • Quantitative HHV-6 testing is performed on blood or affected tissue when assessing active infection.
    • The clinical assessment accounts for possible localized organ infection; a negative plasma result does not exclude localized active infection.
    • When quantitative PCR is performed on whole blood, a viral load greater than 200 copies per mL or 20 copies per microgram of DNA indicates active infection.>200 copies/mL or 20 copies/µg DNA

    Pneumocystis jirovecii Identification Using Amplified Probe

    CPT 87594 was added as MCC in CC1.

    Covered amplified-probe identification: Identification of Pneumocystis jirovecii using amplified probe CPT 87594 meets coverage criteria.

    Rubeola Virus Identification Using Amplified Probe

    CPT 87638 was added as MCC in CC1.

    Covered amplified-probe identification: Identification of Rubeola virus using amplified probe CPT 87638 meets coverage criteria.